Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 7/2019

01-07-2019 | NSCLC | Thoracic Oncology

Survival Benefit of Left Lower Paratracheal (4L) Lymph Node Dissection for Patients with Left-Sided Non-small Cell Lung Cancer: Once Neglected But of Great Importance

Authors: Kejia Zhao, MD, Shiyou Wei, MD, Jiandong Mei, MD, PhD, Chenglin Guo, MD, PhD, Yang Hai, MD, Nan Chen, MD, Lunxu Liu, MD, PhD

Published in: Annals of Surgical Oncology | Issue 7/2019

Login to get access

Abstract

Objective

The aim of this study was to compare survival outcomes between non-small cell lung cancer (NSCLC) patients with or without 4L node dissection (4LND) and to evaluate the potential patient population who will particularly benefit from 4LND.

Methods

Between January 2009 and December 2015, a total of 2063 patients with primary left-sided NSCLC in the Western China Lung Cancer Database were initially reviewed. After exclusion, 1064 patients were enrolled in this study. A total of 460 patients with 4LND (4LND+ group) were matched with 460 patients without 4LND (4LND− group) using propensity-matched analysis. Disease-free survival (DFS) and overall survival (OS) were analyzed.

Results

The metastasis rate of station 4L was 14.6%. Patients with 4LND showed higher DFS (5-year DFS 52.6% vs. 46.7%; hazard ratio [HR] 1.25, 95% confidence interval [CI] 1.03–1.50; p = 0.022) and OS (5-year OS 65.8% vs. 56.3%; HR 1.36, 95% CI 1.10–1.69; p = 0.006) than patients without 4LND. In the multivariate analysis, patients without 4LND (HR 1.33, 95% CI 1.07–1.66; p = 0.011), tumor size > 3 cm, lymph node metastasis, and pathologic stage higher than stage I were independent prognostic factors for poor OS. Subgroup analysis according to pathologic TNM stage and N stage showed that stage II, IIIA, and N2 disease indicated better survival outcomes in the 4LND+ group (p = 0.050, p = 0.016, and p = 0.008, respectively).

Conclusions

Performing 4LND may bring survival benefits to patients with left-sided NSCLC. We suggest 4LND as a standard procedure for left-sided NSCLC patients with stage II or advanced stage disease.
Appendix
Available only for authorised users
Literature
1.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.CrossRef
2.
Vansteenkiste J, De Ruysscher D, Eberhardt WE, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 Suppl 6:vi89–98.CrossRef
3.
Izbicki JR, Passlick B, Pantel K, et al. Effectiveness of radical systematic mediastinal lymphadenectomy in patients with resectable non-small cell lung cancer: results of a prospective randomized trial. Ann Surg. 1998;227(1):138-144.CrossRefPubMedPubMedCentral
4.
Sugi K, Nawata K, Fujita N, et al. Systematic lymph node dissection for clinically diagnosed peripheral non-small-cell lung cancer less than 2 cm in diameter. World J Surg. 1998;22(3):290–4 (discussion 294–5)CrossRefPubMed
5.
Keller SM, Adak S, Wagner H, Johnson DH, Eastern Cooperative Oncology Group. Mediastinal lymph node dissection improves survival in patients with stages II and IIIa non-small cell lung cancer. Ann Thorac Surg. 2000;70(2):358–65 (discussion 356–65)CrossRefPubMed
6.
Wu Y, Huang ZF, Wang SY, Yang XN, Ou W. A randomized trial of systematic nodal dissection in resectable non-small cell lung cancer. Lung Cancer. 2002;36(1):1–6.CrossRefPubMed
7.
Lardinois D, Suter H, Hakki H, Rousson V, Betticher D, Ris HB. Morbidity, survival, and site of recurrence after mediastinal lymph-node dissection versus systematic sampling after complete resection for non-small cell lung cancer. Ann Thorac Surg. 2005;80(1):268–74 (discussion 274–65)CrossRefPubMed
8.
8. Darling GE, Allen MS, Decker PA, et al. Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial. J Thorac Cardiovasc Surg. 2011;141(3):662-670.CrossRefPubMedPubMedCentral
9.
National Comprehensive Cancer Network. NCCN guideline for non-small cell lung cancer. Version 3. NCCN; 2018.
10.
Lardinois D, De Leyn P, Van Schil P, et al. ESTS guidelines for intraoperative lymph node staging in non-small cell lung cancer. Eur J Cardio-thorac Surg. 2006;30(5):787–92.CrossRef
11.
12.
Riquet M, Arame A, Foucault C, Le Pimpec BF. Prognostic classifications of lymph node involvement in lung cancer and current International Association for the Study of Lung Cancer descriptive classification in zones. Interact Cardiovasc Thorac Surg. 2010;11(3):260–4.CrossRefPubMed
13.
Kuzdzal J, Zielinski M, Papla B, et al. Transcervical extended mediastinal lymphadenectomy: the new operative technique and early results in lung cancer staging. Eur J Cardio-thorac Surg. 2005;27(3):384–90 (discussion 390)CrossRef
14.
Wang YN, Yao S, Wang CL, et al. Clinical significance of 4L lymph node dissection in left lung cancer. J Clin Oncol. 2018;36(29):2935–42.CrossRefPubMed
15.
D’Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17(19):2265–81.CrossRefPubMed
16.
Liu L, Che G, Pu Q, et al. A new concept of endoscopic lung cancer resection: Single-direction thoracoscopic lobectomy. Surg Oncol. 2010;19(2):e71–7.CrossRefPubMed
17.
Rusch VW, Asamura H, Watanabe H, Giroux DJ, Rami-Porta R, Goldstraw P. The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol. 2009;4(5):568–77.CrossRefPubMed
18.
Liu C, Pu Q, Guo C, et al. Non-grasping en bloc mediastinal lymph node dissection for video-assisted thoracoscopic lung cancer surgery. BMC surgery. 2015;15(38).
19.
Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6(2):244–85.CrossRefPubMedPubMedCentral
20.
Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2(8):706–14.CrossRefPubMed
21.
Kuroda H, Sakao Y, Mun M, et al. Lymph node metastases and prognosis in left upper division non-small cell lung cancers: the impact of interlobar lymph node metastasis. PLoS One. 2015;10(8):e0134674.CrossRefPubMedPubMedCentral
22.
Sun F, Zhan C, Shi M, et al. Is routine dissection of the station 9 lymph nodes really necessary for primary lung cancer? Int J Surg. 2016;34:53–7.CrossRefPubMed
23.
Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon J, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350(4):351–60.CrossRefPubMed
24.
24. Douillard J, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006;7(9):719–27.CrossRefPubMed
25.
Pignon J, Tribodet H, Scagliotti G, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26(21):3552–9.CrossRefPubMed
26.
Lardinois D, Suter H, Hakki H, Rousson V, Betticher D, Ris H. Morbidity, survival, and site of recurrence after mediastinal lymph-node dissection versus systematic sampling after complete resection for non-small cell lung cancer. Ann Thorac Surg. 2005;80(1):268–74 (discussion 274–65)CrossRefPubMed
27.
Coello M, Luketich J, Litle V, Godfrey T. Prognostic significance of micrometastasis in non-small-cell lung cancer. Clin Lung Cancer. 2004;5(4):214–25.CrossRefPubMed
28.
Silvestri GA, Gonzalez AV, Jantz MA, et al. Methods for staging non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e211S–50S.CrossRefPubMed
29.
30.
31.
31. Watanabe A, Nakazawa J, Miyajima M, et al. Thoracoscopic mediastinal lymph node dissection for lung cancer. Semin Thorac Cardiovasc Surg. 2012;24(1):68–73.CrossRefPubMed
Metadata
Title
Survival Benefit of Left Lower Paratracheal (4L) Lymph Node Dissection for Patients with Left-Sided Non-small Cell Lung Cancer: Once Neglected But of Great Importance
Authors
Kejia Zhao, MD
Shiyou Wei, MD
Jiandong Mei, MD, PhD
Chenglin Guo, MD, PhD
Yang Hai, MD
Nan Chen, MD
Lunxu Liu, MD, PhD
Publication date
01-07-2019
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 7/2019
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-07368-x

Other articles of this Issue 7/2019

Annals of Surgical Oncology 7/2019 Go to the issue

Breast Oncology

Is Breast-Conserving Therapy Appropriate for Male Breast Cancer Patients? A National Cancer Database Analysis

Breast Oncology

Borderline and Malignant Phyllodes Tumors: How Often do They Locally Recur and is There Anything we can do About it?

Thoracic Oncology

Predictive Value of Body Mass Index for Short-Term Outcomes of Patients with Esophageal Cancer After Esophagectomy: A Meta-analysis

Breast Oncology

Tumor Heterogeneity Correlates with Less Immune Response and Worse Survival in Breast Cancer Patients

Pancreatic Tumors

Exosomes from Pancreatic Juice: A Step Closer to the Holy Grail?

ASO Author Reflections

ASO Author Reflections: Surgical Treatment for Male Breast Cancer in the Modern Era